08:00 , Dec 23, 2013 |  BC Week In Review  |  Company News

Vermillion management update

Vermillion Inc. (NASDAQ:VRML), Austin, Texas   Business: Diagnostic   Hired: Marian Sacco as SVP of sales and marketing and chief commercial officer, formerly SVP of sales and marketing at Adeza Biomedical Corp., which Cytyc Corp....
07:00 , Mar 21, 2011 |  BioCentury  |  Politics, Policy & Law

Only the pricing is new

KV Pharmaceutical Co. last week drew congressional attention over the pricing of its newly approved Makena hydroxyprogesterone caproate to prevent preterm birth in women with a history of preterm delivery. The planned pricing - $1,500 per...
07:00 , May 28, 2007 |  BC Week In Review  |  Company News

Cytyc, Hologic deal

Women's health diagnostic companies HOLX and CYTC will merge. CYTC shareholders will receive $16.50 in cash and 0.52 HOLX shares for each CYTC share owned, which the companies valued at $6.2 billion. CYTC shareholders will...
07:00 , Apr 9, 2007 |  BC Week In Review  |  Company News

Adeza, Cytyc deal

CYTC completed its previously announced acquisition of ADZA for $452 million, or $24 per share, in cash (see BioCentury, Feb. 19). ADZA is now called Cytyc Prenatal Products Corp. and will operate as a CYTC...
08:00 , Mar 5, 2007 |  BC Week In Review  |  Company News

Cytyc, Adiana Inc. deal

CYTC agreed to acquire Adiana for $60 million in cash up front, plus up to $155 million in milestones and royalties over four years. Adiana is developing the Complete TCS device to perform non-incisional, permanent...
08:00 , Feb 19, 2007 |  BC Week In Review  |  Company News

Adeza, Cytyc deal

CYTC agreed to acquire women’s health company ADZA for $452 million, or $24 per share, in cash. The price is a 55% premium to ADZA’s close of $15.53 on Feb. 9, the last trading day...
08:00 , Feb 19, 2007 |  BioCentury  |  Finance

Ebb & Flow

When Invitrogen bought BioReliance for $500 million in cash in early 2004, the rationale was clear: make a bioproduction powerhouse by coupling services with products. The deal combined IVGN's media, sera, reagents, packaging and cell...
01:14 , Feb 13, 2007 |  BC Extra  |  Company News

Cytyc to acquire Adeza

CYTC agreed to acquire women's health company ADZA for $24 per share, or $452 million. The price is a 55% premium to ADZA's close of $15.53 on Friday. The deal will give CYTC, which markets...
08:00 , Feb 5, 2007 |  BC Week In Review  |  Clinical News

Gestiva regulatory update

FDA granted Orphan Drug designation for Gestiva to prevent preterm birth in women with a history of preterm delivery. ADZA received an approvable letter from FDA for Gestiva requesting an additional animal study and "certain...
08:00 , Jan 1, 2007 |  BioCentury  |  Finance

4Q setbacks

4Q setbacks 4Q setbacks Selected fourth quarter product setbacks Company Setback Adeza (ADZA) Receives FDA approvable letter for Gestiva, a long acting form of a naturally occurring progesterone, to prevent preterm birth in women with...